Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Use of Genetic Blueprint of Sea Squirts to Produce Natural Drug For Cancer
Using a partial synthetic process, by extracting trabectedin or ET-743, a compound found in marine invertebrate., scientists are producing a natural cancer drug. They are isolating the genetic blueprint of the ET-743's producer by using advanced sequencing techniques. The insights will make it possible for scientists to culture the bacteria in the laboratory without its host.
- Read more about Japanese pharma cos showing interest in contract manufacturing services from India
Japanese pharmaceutical industry comprising of both multinationals and generic companies, have shown keen interest in working with the Indian counterparts in contract manufacturing service space.
- Read more about Cipla signs agreement with Serum Institute to introduce flu vaccine Nasovac-S in India
The pharmaceutical major Cipla Limited has signed an pact with Serum Institute of India Ltd (SII) to exclusively market flu vaccine Nasovac-S in India. Under this agreement, SII will develop and manufacture the vaccine, and Cipla will market it in India. The vaccine will be manufactured in Serum’s world class production facilities approved by the WHO.
- Read more about First edition of ‘Advantage Health Care - India 2015’ held in Delhi from October 5-7
FICCI launched the first edition of ‘Advantage Health Care - India 2015’, which will be held from October 5-7, 2015 at Pragati Maidan, New Delhi. The objective of ‘Advantage Health Care - India 2015’ is to promote India as a premier global healthcare destination and to enable streamlined medical services exports from India.
- Read more about E coli turn in to antibiotic producing factories
Like a dairy farmer tending to a herd of cows to produce milk, researchers are tending to colonies of the bacteria Escherichia coli (E. coli) to produce new forms of antibiotics — including three that show promise in fighting drug-resistant bacteria.
- Read more about Taro Pharma's net income raise by 70% to US$ 153 mn in Q4
Taro Pharmaceutical Industries has posted strong net profit growth of 70 per cent during the fourth quarter ended March 2015 to US$ 153 million from $90 million in the similar period of last year. Its net sales up by 30.5 per cent to $244 million from $187 million. With smart improvement in earnings, EPS worked out to $3.56 as against $2.10 in the last period. Its R&D expenses raised to $23.9 million from $13.1 million and selling, marketing, general and administrative expenses declined by 16.5 per cent to $22.2 million from $26.6 million.
- Read more about Indoco Remedies standalone net profit up to Rs.18.75 cr, dividend at 80%
Indoco Remedies, has posted its standalone net profit during the fourth quarter ended March 2015 to Rs.18.75 crore from Rs.18.55 crore in the corresponding quarter of last year due to higher R&D expenditure. Its R&D expenditure increased by 78.2 per cent to Rs.7.45 crore from Rs.4.18 crore. The company's standalone net sales increased by 13.8 per cent to Rs.211.59 crore from Rs.185.86 crore. Its EBIDTA moved up by 11.2 per cent to Rs.37.66 crore from Rs.33.88 crore. EPS remained almost same at Rs.2.03. The board of directors has recommended equity dividend of 80 per cent i.e. Rs.1.60 per share for the year 2014-15.
- Read more about US FDA Approves Neupogen as First Drug To Treat Sickness Due to Radiation Exposure
US Food and Drug Administration (FDA) has approved Neupogen, a drug originally used to treat side effects of chemotherapy,is the first ever approved for the treatment of acute radiation injury and the approval came as a result of research performed by the University of Maryland School of Medicine (UM SOM) scientists.
- Read more about Janssen's Imbruvica get EMA recommendation to treat Waldenstrom’s macroglobulinaemia
The European Medicines Agency (EMA) has recommended extending the use of Imbruvica (ibrutinib) for treatment of patients with Waldenstrom’s macroglobulinaemia. The medicine is indicated for adults who have received at least one prior therapy or as a first line treatment for patients unsuitable for chemo-immunotherapy.

[adsense:336x280:8701650588]
- Read more about Aura Biosciences receives US FDA orphan drug designation for novel treatment of uveal melanoma
The US Food and Drug Administration (FDA) granted Orphan Drug Designation to Aura Biosciences' drug AU-011 for the treatment of uveal melanoma. The FDA’s Orphan Drug Designation programme provides orphan status to drugs and biologics, which demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions in the US.